Psychiatria pre prax 1/2011
Agomelatine – first results from trial VALID in Slovakia
Agomelatine is a novel antidepressant. In this paper we presented first results from trial VALID. Valid trial was opern multicentric study performed in Slovakia in years 2009 – 2010. In this paper we evaluated treatment effect in 65 patients with depression (average age 45,28 years). Dosis of agomelatine was 25 – 50 mg daily. According Mean MADRS global score (in Observed Case population) improved from baseline level of 28,90 to the endpoint (week 8) value of 10,2 (p < 0,0001). All MADRS items improved significantly. Also CGI score improved significantly (from 4,54 to 1,86, p = 0,00001).
Keywords: agomelatine, antidepressant effect, multicentric trial VALID in Slovakia.
